JMP Securities Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective decreased by JMP Securities from $19.00 to $18.00 in a research note issued to investors on Wednesday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on ZVRA. Wall Street Zen cut Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 20th. Cantor Fitzgerald raised their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Finally, HC Wainwright assumed coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and a consensus target price of $23.71.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $9.43 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 2.93. The company has a market capitalization of $529.31 million, a PE ratio of -44.90 and a beta of 1.87. Zevra Therapeutics has a one year low of $6.19 and a one year high of $13.16. The business has a 50 day simple moving average of $10.56 and a 200 day simple moving average of $8.75.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $1.43 by ($1.49). The company had revenue of $25.88 million for the quarter, compared to the consensus estimate of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. On average, sell-side analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its stake in shares of Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth $53,000. GAMMA Investing LLC grew its stake in shares of Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after purchasing an additional 8,020 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the period. Finally, Creative Planning acquired a new stake in shares of Zevra Therapeutics during the second quarter worth $92,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.